Alteon to Present at the Credit Suisse First Boston Healthcare Conference Friday, November 19, 2004
11 Noviembre 2004 - 10:48AM
PR Newswire (US)
Alteon to Present at the Credit Suisse First Boston Healthcare
Conference Friday, November 19, 2004 PARSIPPANY, N.J., Nov. 11
/PRNewswire-FirstCall/ -- Alteon Inc. (AMEX: ALT) announced today
that Kenneth I. Moch, President and Chief Executive Officer, will
present a company update at the Credit Suisse First Boston
Healthcare Conference, being held at the Arizona Biltmore in
Phoenix, on Friday, November 19, 2004, 7:30 a.m., MT. The
presentation will be webcast live and will be accessible in the
Investor Relations section of Alteon's website,
http://www.alteon.com/, where it also will be archived for 30 days
after the event. About Alteon Alteon is developing several new
classes of drugs that have shown the potential to reverse or slow
down diseases of ageing and complications of diabetes. These
compounds have an impact on a fundamental pathological process
caused by the progressive formation of protein-glucose complexes
called Advanced Glycation End-products (A.G.E.s). The formation and
crosslinking of A.G.E.s lead to a loss of flexibility and function
in body tissues and organs and have been shown to be a causative
factor in many age- related diseases and diabetic complications.
Alteon has created a library of novel classes of compounds
targeting the A.G.E. Pathway. Alteon's lead compound alagebrium
chloride (formerly ALT-711), the only A.G.E. Crosslink Breaker in
advanced human testing, has demonstrated safety and efficacy in
several Phase 2 trials and is actively being developed for systolic
hypertension and heart failure. Over 1200 patients have been
involved in alagebrium's human clinical trials to date, of whom
approximately 900 have received active compound. Ongoing clinical
trials include the phase 2b systolic hypertension trial, SPECTRA
(Systolic Pressure Efficacy and Safety Trial of Alagebrium), and
the phase 2a heart failure trial, PEDESTAL (Patients with Impaired
Ejection Fraction and Diastolic Dysfunction: Efficacy and Safety
Trial of ALagebrium), as well as a third trial exploring mechanism
of action in endothelial dysfunction. For more detailed scientific
information about alagebrium, please visit the scientific
publications section of the Alteon website, http://www.alteon.com/.
Any statements contained in this press release that relate to
future plans, events or performance are forward-looking statements
that involve risks and uncertainties including, but not limited to,
those relating to technology and product development (including the
possibility that early clinical trial results may not be predictive
of results that will be obtained in large-scale testing or that any
clinical trials will not demonstrate sufficient safety and efficacy
to obtain requisite approvals or will not result in marketable
products), regulatory approval processes, intellectual property
rights and litigation, competitive products, ability to obtain
financing, and other risks identified in Alteon's filings with the
Securities and Exchange Commission. The information contained in
this press release is accurate as of the date indicated. Actual
results, events or performance may differ materially. Alteon
undertakes no obligation to publicly release the result of any
revision to these forward-looking statements that may be made to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events. DATASOURCE: Alteon Inc.
CONTACT: Susan M. Pietropaolo, Director of Corporate Communications
& Investor Relations for Alteon Inc., +1-201-818-5537 Web site:
http://www.alteon.com/
Copyright